GPX4 and diffuse large B-cell lymphoma: Immunohistochemical analyses have classified DLBCL patients into GPX4-positive and GPX4-negative groups, revealing that GPX4 positivity correlates with significantly poorer overall (OS) and progression-free survival (PFS).